Early treatment with lorlatinib improves survival in some lung cancer patients

Lung cancer patients with a specific genetic alteration lived longer and were protected against metastasis to the brain when treated early with the drug lorlatinib (Lorbrena), according to a study led by researchers at Massachusetts General Hospital (MGH), published in the New England Journal of Medicine (NEJM).